Elanco reports Q4 revenue up 12% to $1.14B, net loss $276M; provides 2026 guidance in line with outlook

Elanco Animal Health Inc

2025-FY EPS reported -$0.47 revenue$4,715,000,000

Q4 2025 revenue $1,144M (+12% reported, +9% organic CC); reported net loss $276M, adjusted EPS $0.13.
FY 2025 revenue $4,715M (+6% reported, +7% organic CC); reported net loss $232M, adjusted EPS $0.94.
2026 guidance: revenue $4,950-5,020M (4-6% organic CC growth), adjusted EBITDA $955-985M, adjusted EPS $1.00-1.06.
Raising 2026 innovation revenue target to $1.15B; delivered all 'Big 6' blockbuster products by end of 2025 with Befrena approval in Q4.
Recorded $155M restructuring charges in Q4 under Elanco Ascend; net leverage ratio improved to 3.6x.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.